PPARD and psoriasis: To assess the requirement of Th17 cells for PPARβ/δ - mediated skin disease, we depleted them in vivo by intraperitoneal injection of anti-IL12/23p40, analogous to the monoclonal antibody (ustekinumab) used to treat psoriasis.